MA71266A - Procédés d'intervention précoce pour prévenir ou améliorer la toxicité - Google Patents

Procédés d'intervention précoce pour prévenir ou améliorer la toxicité

Info

Publication number
MA71266A
MA71266A MA71266A MA71266A MA71266A MA 71266 A MA71266 A MA 71266A MA 71266 A MA71266 A MA 71266A MA 71266 A MA71266 A MA 71266A MA 71266 A MA71266 A MA 71266A
Authority
MA
Morocco
Prior art keywords
ameliaze
toxicity
prevent
early intervention
intervention methods
Prior art date
Application number
MA71266A
Other languages
English (en)
Inventor
Michael Jensen
Rebecca Gardner
Original Assignee
Seattle Children's Hospital(DBA Seattle Children's Research Institute)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58609964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA71266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Children's Hospital(DBA Seattle Children's Research Institute) filed Critical Seattle Children's Hospital(DBA Seattle Children's Research Institute)
Publication of MA71266A publication Critical patent/MA71266A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA71266A 2016-03-22 2017-03-22 Procédés d'intervention précoce pour prévenir ou améliorer la toxicité MA71266A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US201662429722P 2016-12-02 2016-12-02
EP24221056.5A EP4545143A3 (fr) 2016-03-22 2017-03-22 Procédés d'intervention précoce pour prévenir ou améliorer la toxicité

Publications (1)

Publication Number Publication Date
MA71266A true MA71266A (fr) 2025-04-30

Family

ID=58609964

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71266A MA71266A (fr) 2016-03-22 2017-03-22 Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
MA044486A MA44486A (fr) 2016-03-22 2017-03-22 Procédés d'intervention précoce pour prévenir ou atténuer la toxicité

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA044486A MA44486A (fr) 2016-03-22 2017-03-22 Procédés d'intervention précoce pour prévenir ou atténuer la toxicité

Country Status (13)

Country Link
US (5) US11518814B2 (fr)
EP (3) EP4015536A1 (fr)
JP (3) JP7048571B2 (fr)
KR (1) KR20190021200A (fr)
CN (1) CN109476743A (fr)
AU (2) AU2017238218B2 (fr)
BR (1) BR112018069251A2 (fr)
CA (1) CA3018588A1 (fr)
ES (1) ES2907557T3 (fr)
MA (2) MA71266A (fr)
MX (1) MX2018011480A (fr)
RU (1) RU2018136877A (fr)
WO (1) WO2017165571A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (fr) 2012-12-20 2019-10-23 Purdue Research Foundation Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
WO2017096331A1 (fr) 2015-12-04 2017-06-08 Juno Therapeutics, Inc. Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
CN109476743A (zh) 2016-03-22 2019-03-15 西雅图儿童医院(以西雅图儿童研究所名义营业) 预防或缓解毒性的早期干预方法
CA3019835A1 (fr) 2016-04-08 2017-10-12 Purdue Research Foundation Methodes et compositions pour therapie par lymphocytes t car
US20200078400A1 (en) * 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019089848A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés associés à une charge tumorale pour évaluer une réponse à une thérapie cellulaire
MA51210A (fr) * 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
WO2019144095A1 (fr) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Procédés d'utilisation de cellules t car
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
CA3091339A1 (fr) * 2018-02-16 2019-08-22 Incyte Corporation Inhibiteurs de la voie jak1 pour le traitement de troubles lies aux cytokines
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
WO2019170845A1 (fr) * 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Antagoniste de l'il-1 et toxicité induite par la thérapie cellulaire
US20210263045A1 (en) * 2018-04-06 2021-08-26 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (fr) * 2019-08-12 2021-02-18 Sitokine Limited Compositions et méthodes de traitement du syndrome de libération de cytokines et de neurotoxicité
CA3147444A1 (fr) * 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Procede de blocage ou d'amelioration du syndrome de liberation des cytokines
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2022072515A1 (fr) * 2020-09-29 2022-04-07 Washington University Procédés pour déterminer un risque de neurotoxicité
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
AU2022270072A1 (en) 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2026092543A1 (fr) * 2024-10-29 2026-05-07 Shenzhen Genocury Biotech Co., Ltd Procédés et compositions de traitement prophylactique pour prévenir un crs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
WO2000014257A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2007147623A2 (fr) * 2006-06-22 2007-12-27 Cellact Pharma Gmbh Nouvelle cible dans le traitement du syndrome de libération de cytokines (crs)
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (fr) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Systèmes de traitement d'échantillons et procédés
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2735456C (fr) 2008-08-26 2021-11-16 City Of Hope Procede et compositions pour fonctionnement ameliore d'effecteur antitumoral de lymphocytes t
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (fr) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Méthodes et compositions pour une immunothérapie cellulaire
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (fr) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
PL4019041T3 (pl) * 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017035362A1 (fr) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Utilisation de composés inhibiteurs de la voie du complément pour atténuer des réponses immunitaires indésirables associées à une thérapie adoptive par lymphocytes t
WO2017040930A2 (fr) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarqueurs prédictifs du syndrome de libération de cytokines
CN109476743A (zh) 2016-03-22 2019-03-15 西雅图儿童医院(以西雅图儿童研究所名义营业) 预防或缓解毒性的早期干预方法
EP3484455A2 (fr) 2016-07-15 2019-05-22 Novartis AG Traitement et prévention du syndrome de libération de cytokine à l'aide d'un récepteur d'antigène chimérique en combinaison avec un inhibiteur de kinase

Also Published As

Publication number Publication date
AU2017238218B2 (en) 2024-05-02
US20230212298A1 (en) 2023-07-06
WO2017165571A1 (fr) 2017-09-28
CA3018588A1 (fr) 2017-09-28
US20230322937A1 (en) 2023-10-12
US20230091447A1 (en) 2023-03-23
EP4015536A1 (fr) 2022-06-22
MA44486A (fr) 2019-01-30
EP4545143A2 (fr) 2025-04-30
EP3433276A1 (fr) 2019-01-30
CN109476743A (zh) 2019-03-15
MX2018011480A (es) 2019-03-28
JP2019509351A (ja) 2019-04-04
JP7048571B2 (ja) 2022-04-05
EP4545143A3 (fr) 2025-07-23
ES2907557T3 (es) 2022-04-25
US20240425608A1 (en) 2024-12-26
JP7528143B2 (ja) 2024-08-05
KR20190021200A (ko) 2019-03-05
BR112018069251A2 (pt) 2019-01-22
RU2018136877A (ru) 2020-04-22
JP2024156736A (ja) 2024-11-06
JP2022088489A (ja) 2022-06-14
US12098208B2 (en) 2024-09-24
US20190112379A1 (en) 2019-04-18
EP3433276B1 (fr) 2021-12-22
AU2017238218A1 (en) 2018-10-11
US11760804B2 (en) 2023-09-19
US11518814B2 (en) 2022-12-06
AU2024205049A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MA44486A (fr) Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3430731A4 (fr) Architecture d'iugw
EP3479493A4 (fr) Détermination d'emplacements d'émetteur
EP3324840A4 (fr) Tensiomètre pour l'estimation de débit
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
EP3387025A4 (fr) Compositions d'émulsion inverse
EP3325963A4 (fr) Amélioration de l'estimation de globules
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
EP3040355A4 (fr) Modificateur d'asphalte et composition d'asphalte le contenant
EP3443293A4 (fr) Capteurs d'effort
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3484444A4 (fr) Composition d'émulsion de pickering
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP3322451A4 (fr) Réduction ou prévention électrochimique d'infections
EP3431808A4 (fr) Butée d'arrêt
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP3479837A4 (fr) Composition améliorant l'anémie rénale
EP3444345A4 (fr) Dérivé d'arnmicro-143
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3297632A4 (fr) Clairance de galantamine d'amyloides
EP3634226A4 (fr) Détermination d'indicateur
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3458432A4 (fr) Composition d'engrais